This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VIVUS Announces Date Of First Quarter 2013 Financial Results And Conference Call

MOUNTAIN VIEW, Calif., May 1, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the first quarter ended March 31, 2013 before the NASDAQ Market opens on Wednesday, May 8, 2013. The company will conduct a conference call and an audio webcast at 8:30am EDT the same day.

Date:   May 8, 2013

Time:   8:30 AM EDT

Listen via Internet: http://ir.vivus.com/

U.S. Toll-free: 877-359-2916

Outside U.S.: (+) 224-357-2386

A webcast replay will be available on the VIVUS website for 30 days.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. For more information about the company, please visit www.vivus.com .

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "estimate," "expect", "forecast," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2012, and periodic reports filed with the Securities and Exchange Commission.

CONTACT: VIVUS, Inc.
         Timothy E. Morris
         Chief Financial Officer
         morris@vivus.com
                  
         Dana B. Shinbaum
         shinbaum@vivus.com
         
         Investor Relations:
         The Trout Group
         Brian Korb
         bkorb@troutgroup.com
         646-378-2923
         
         Morrow & Co., LLC
         Joseph J. Mills
         jmills@morrowco.com
         203-658-9423
         
         Media Relations:
         GolinHarris
         Ashley Buford
         abuford@golinharris.com
         (212) 373-6045
         
         Joele Frank, Wilkinson Brimmer Katcher
         Matthew Sherman | Jennifer Beugelmans
         msherman@joelefrank.com | jbeugelmans@joelefrank.com
         212-235-2665 | 212-895-8692

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs